Binds Oligosaccharide Structure Patents (Class 530/387.5)
-
Publication number: 20090264507Abstract: The present invention provides methods for diagnosing and providing a prognosis for wound healing in a patient by characterizing and analyzing the single nucleotide polymorphism (SNP) of a wound healing associated gene wit3.0. In particular, the invention provides a method of diagnosis and prognosis of oral disease-wound healing, including gingival periodontitis and residual alveolar bone resorption, by characterizing and analyzing the wound inducible transcript-3.0 (wit3.0)SNP pattern in a sample of a patient with and without susceptibility for the disease.Type: ApplicationFiled: March 10, 2006Publication date: October 22, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Ichiro Nishimura, Audrey Lin, Neal Garret
-
Publication number: 20090263823Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: ApplicationFiled: June 13, 2007Publication date: October 22, 2009Inventors: Kazuhiro Matsuda, Yuko Shingu
-
Publication number: 20090246200Abstract: The present invention presents the isolation, characterization and synthesis of oligosaccharides of Bacillus anthracis. Also presented are antibodies that bind to such saccharide moieties and various methods of use for such saccharide moieties and antibodies.Type: ApplicationFiled: December 24, 2008Publication date: October 1, 2009Inventors: Russell W. Carlson, Geert-Jan Boons, Therese Buskas, Biswa Choudhury, Elmar Kannenberg, Christine Leoff, Alok Mehta, Elke Saile, Jana Rauvolfova, Conrad Quinn, Patricia Wilkins, Mahalakshmi Vasan, Margreet A. Wolfert
-
Publication number: 20090215993Abstract: Described are immunogenic compounds useful for generation of antibodies which are highly specific for mycophenolic acid which do not react or have substantially no cross-reactivity with the glucuronide metabolites of mycophenolic acid, especially the acyl-glucuronide metabolite.Type: ApplicationFiled: October 24, 2008Publication date: August 27, 2009Inventors: Mitali Ghoshal, Raymond Hui, Shaker Rashid
-
Publication number: 20090136964Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swam tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.Type: ApplicationFiled: March 31, 2006Publication date: May 28, 2009Applicant: Seikagaku corporation Central research LaboratorieInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
-
Patent number: 7531633Abstract: A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.Type: GrantFiled: December 20, 2004Date of Patent: May 12, 2009Assignee: Nabi BiopharmaceuticalsInventors: Viliam Pavliak, Ali Ibrahim Fattom
-
Publication number: 20090118141Abstract: The present invention provides methods for identifying oligosaccharides specific to an inflammatory or infectious disease, methods for diagnosing an inflammatory or infectious disease by detecting the presence or absence of such oligosaccharides, and methods for treating an inflammatory or infectious disease by administering antibodies directed to such oligosaccharides. The present invention also provides methods for diagnosing ocular rosacea by determining the presence or absence of specific oligosaccharide markers. In addition, the present invention provides markers for ocular rosacea comprising 0-linked oligosaccharides as well as kits for diagnosing or treating ocular rosacea.Type: ApplicationFiled: May 3, 2006Publication date: May 7, 2009Applicant: The Regents of the University of CaliforniaInventors: Carlito B. Lebrilla, Hyunjoo An, Lenio S. Alvarenga, Mark D. Mannis
-
Publication number: 20080317771Abstract: The invention concerns anti-clusterin oligoclonal antibodies able to recognize and bind in a selective and specific way antigenic epitopes of clusterin isoforms to be used in tumours diagnosis and in the prediction of their malignancy grade, diagnostic method and related kits.Type: ApplicationFiled: February 17, 2005Publication date: December 25, 2008Inventors: Luigi Giusto Spagnoli, Sabina Pucci, Elena Bonanno, Flavia Pichiorri, Gennaro Citro
-
Publication number: 20080299122Abstract: The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function.Type: ApplicationFiled: May 23, 2007Publication date: December 4, 2008Applicant: UCB SAInventors: Leon Fernando Garcia-Martinez, Yuching Chen, Dawn Andrews
-
Publication number: 20080299123Abstract: The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy.Type: ApplicationFiled: October 5, 2007Publication date: December 4, 2008Inventors: Peter Altevogt, Alexander Stoeck, Daniela Gast, Susanne Sebens Muerkoster, Heiner Schafer
-
Patent number: 7449553Abstract: A neutral/alkaline ceramidase derived from a mammal; an antibody specifically binding thereto; a probe and primer which are capable of specifically hybridizing thereto; a method for producing the ceramidase by a genetic engineering means; a method for detecting the ceramidase or the gene; and a method of controlling an amount of a ceramide in a cell and/or in a tissue. The present invention is useful as a reagent for lipid engineering for analyzing a structure, functions, and the like of a ceramide, and in its applications to diseases associated with the ceramide metabolism.Type: GrantFiled: April 6, 2007Date of Patent: November 11, 2008Assignee: Takara Bio Inc.Inventor: Makoto Ito
-
Patent number: 7435797Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chainsType: GrantFiled: April 9, 2003Date of Patent: October 14, 2008Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
-
Publication number: 20080226627Abstract: This application is based, inter alia, on the discovery of a binding interaction between the Hn-33 hemagglutinin polypeptide of the type A Clostridium botulinum neurotoxin complex and synaptosomal proteins, including synaptotagmin II (Syt II). Methods of screening for compounds that modulate, e.g., increase or decrease, this interaction are provided. Also provided are compositions and methods for targeting compounds to neuronal and cancer cells by coupling the compounds to Hn-33 or biologically active Hn-33 variants.Type: ApplicationFiled: April 18, 2006Publication date: September 18, 2008Inventors: Bal Ram Singh, Yu Zhou
-
Patent number: 7423126Abstract: A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below: (a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or (b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I: GlcNAc?1-3Gal?1-4GlcNAc ??(I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, ?1-3 represents a ?1-3 glycosidic linkage, and ?1-4 represents a ?1-4 glycosidic linkage.Type: GrantFiled: October 15, 2004Date of Patent: September 9, 2008Assignee: Aichi PrefectureInventor: Reiji Kannagi
-
Publication number: 20080213268Abstract: Novel anti-NRP1 antibodies and variants thereof having unique structural and functional characteristics are disclosed. Also provided are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: April 22, 2008Publication date: September 4, 2008Inventors: Ryan J. Watts, Yan Wu
-
Publication number: 20080199879Abstract: The present invention is intended to devise a process of measuring ?-amyloid in a biological sample such as blood and to apply the process to diagnosis of Alzheimer's disease. It is possible to assay Alzheimer's disease by measuring a total amount of ?-amyloid 1-42 and ?-amyloid 1-42 fragments each of which retains a C-terminal site of the ?-amyloid 1-42 in the biological sample by an immunological assay in which an antibody which recognizes the C-terminal site of ?-amyloid 1-42 is used. It is preferable that the immunological assay be a competitive immunological assay.Type: ApplicationFiled: October 27, 2005Publication date: August 21, 2008Applicant: SANKO JUNYAKU CO., LTD.Inventors: Shigeo Takayama, Yuji Yamada
-
Patent number: 7399636Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: December 31, 2002Date of Patent: July 15, 2008Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7396917Abstract: Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.Type: GrantFiled: December 2, 2002Date of Patent: July 8, 2008Assignee: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, Shana Frederickson, Mark Renshaw
-
Publication number: 20080127368Abstract: The present invention relates to a polypeptide which belongs to the R3R3-type MYB family and which regulates the shikimate pathway towards the production of benzenoids. The shikimate pathway is a biosynthesis pathway through which the three essential aromatic amino acids tyrosine, phenylalanine and tryptophan are synthesized in plants, bacteria and fungi. The present invention provides for the first time a regulatory protein in the shikimate pathway and a means to regulate the biosynthesis of these three essential amino acids which cannot be produced by mammals. At the same time, it opens up the way for the regulation of the biosynthesis of aromatic and non-aromatic compounds which are derived from these essential amino acids.Type: ApplicationFiled: September 1, 2005Publication date: May 29, 2008Inventors: Michel Albertus Haring, Robert Cornelis Schuurink, Julian Cornelis Verdonk, Arjen J. VanTunen
-
Publication number: 20080118509Abstract: The present invention provides an isolated specific binding member capable of binding a sialyltetraosly carbohydrate and directly inducing cell death without the need for immune effector cells. Such a binding member may be an antibody or a part thereof. Also provided are the use of such binding members in medicine and nucleic acids encoding such binding members.Type: ApplicationFiled: May 11, 2005Publication date: May 22, 2008Inventors: Linda Gillian Durrant, Tina Parsons
-
Patent number: 7355012Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.Type: GrantFiled: September 25, 2002Date of Patent: April 8, 2008Assignee: United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
-
Patent number: 7341994Abstract: GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing the same.Type: GrantFiled: April 23, 2001Date of Patent: March 11, 2008Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Dai Ishikawa, Koichi Ogino, Takao Taki
-
Patent number: 7285642Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: October 23, 2007Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7285391Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 1, 2004Date of Patent: October 23, 2007Assignee: The Trustees of Columbia Univeristy in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 7253263Abstract: The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives.Type: GrantFiled: September 29, 2000Date of Patent: August 7, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Nobuo Hanai, Kenya Shitara, Kazuyasu Nakamura, Rinpel Niwa
-
Patent number: 7235644Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.Type: GrantFiled: March 15, 2006Date of Patent: June 26, 2007Assignee: United States of America as represented by the Secretary of the ArmyInventors: Apurba Bhattacharjee, Alan Cross, Jerald Sadoff, Wendell Zollinger
-
Patent number: 7198954Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: August 1, 2000Date of Patent: April 3, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7148329Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of auto-immune diseases, the treatment of allergy, and/or for inhibiting HIV infection. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins.Type: GrantFiled: April 19, 2000Date of Patent: December 12, 2006Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7064191Abstract: The present invention relates to a process for purifying an antibody having a desired property, which comprises using a substance having an affinity to a carbohydrate binding to the antibody; a medicament comprising, as an active ingredient, the antibody purified by the process; and a method for diagnosing or preventing various diseases, which comprises using a substance having an affinity to a carbohydrate binding to an antibody.Type: GrantFiled: October 4, 2001Date of Patent: June 20, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Toyohide Shinkawa, Kazuhisa Uchida, Motoo Yamasaki, Emi Hosaka, Kenya Shitara
-
Patent number: 7060495Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.Type: GrantFiled: December 12, 1997Date of Patent: June 13, 2006Assignee: Behrinwerke AktienegesellschaftInventors: Mathias Gehrmann, Gerhard Seemann, Klaus Bosslet, Jörg Czech
-
Patent number: 7049407Abstract: A variety of heparanase specific antibodies which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific antibodies for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific antibodies for therapy of a condition associated with expression of heparanase; the use of a heparanase specific antibodies for quantification of heparanase in a body fluid; the use of a heparanase specific antibodies for targeted drug delivery; and the use of a heparanase specific antibodies as a therapeutic agent.Type: GrantFiled: January 16, 2001Date of Patent: May 23, 2006Assignees: InSight Biopharmaceuticals Ltd., Hadasit Medical Research Services and Development Ltd.Inventors: Iris Pecker, Israel Vlodavsky, Yael Friedman, Tuvia Perets
-
Patent number: 7030228Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.Type: GrantFiled: November 15, 2000Date of Patent: April 18, 2006Assignee: Miltenyi Biotec GmbHInventors: Juergen Schmitz, Andrzej Dzionek, David William Buck
-
Patent number: 7026287Abstract: The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.Type: GrantFiled: May 12, 2003Date of Patent: April 11, 2006Inventors: Jerome Owen Cantor, Bronislava Shteyngart
-
Patent number: 6927034Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: May 13, 1999Date of Patent: August 9, 2005Assignee: The Trustees of Columbia University in the City of New YorkInventors: John O'Connor, Steven Birken, Galina Kovalevskaya
-
Patent number: 6887673Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.Type: GrantFiled: July 30, 2003Date of Patent: May 3, 2005Assignee: Bristol-Myers Squibb CompanyInventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
-
Ligands directed to the non-secretory component, non-stalk region of plgR and methods of use thereof
Patent number: 6855810Abstract: The invention provides compositions and methods for specific binding to a region of the polymeric immunoglobulin receptor (pIgR) of a cell with the provisos that the ligand does not substantially bind to the most abundant form of the secretory component (SC) of pIgR present in an organ of interest of an animal of interest under physiological conditions, and does not bind to the pIgR stalk. In some embodiments, the ligand decreases cleavage of SC from the stalk by at least one-third. The ligands and methods of the invention can be used with both birds and mammals. In more preferred embodiments, the animal is a mammal. In the most preferred embodiment, the animal is a human. The ligand may be targeted into the cell or may undergo retrograde transcytosis and release at the basolateral side of the cell, and may comprise a biologically active composition.Type: GrantFiled: March 26, 2001Date of Patent: February 15, 2005Assignee: The Regents of the university of CaliforniaInventors: Keith E. Mostov, Steven J. Chapin, Janice Richman-Eisenstat -
Patent number: 6835545Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: April 16, 2001Date of Patent: December 28, 2004Assignee: President and Fellows of Harvard CollegeInventor: Jose Halperin
-
Patent number: 6808710Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.Type: GrantFiled: August 23, 2000Date of Patent: October 26, 2004Assignees: Genetics Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Clive Wood, Gordon J. Freeman
-
Patent number: 6803039Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.Type: GrantFiled: May 16, 2001Date of Patent: October 12, 2004Assignee: Japan Tobacco Inc.Inventors: Takashi Tsuji, Katsunari Tezuka, Nobuaki Hori
-
Patent number: 6770277Abstract: The gene for Streptococcus pyogenes DNase B has been cloned and vectors incorporating the cloned DNA have been used to transform Escherichia coli, allowing efficient and rapid production of the DNase in E. coli without the necessity of growing large quantities of S. pyogenes. The enzyme can be produced with a leader peptide at its aminoterminus. An improved method for the purification of naturally occurring S. pyogenes DNase B enzyme is also provided. The DNase B enzyme produced, either by purification of naturally occurring enzyme or by recombinant DNA techniques, can be used to generate antibodies and can also be used in immunochemical assays to detect the presence of anti-DNase B antibodies in serum as a marker of infection by S. pyogenes.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 2004Assignee: Beckman Coulter, Inc.Inventors: Craig W Adams, Patty P. Y. Pang, C. Marina Belei
-
Patent number: 6759519Abstract: Antibodies against human G-protein chemokine receptor polypeptides, the polypeptides themselves, DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: GrantFiled: June 25, 1999Date of Patent: July 6, 2004Assignee: Human Genome Sciences, Inc.Inventors: Yi Li, Steven M. Ruben
-
Patent number: 6693177Abstract: The invention relates to a novel process for preparation of a biomarker specific for O-acetylated sialic acid and useful for the diagnosis, monitoring outcome of treatment and prediction of relapse of acute lymphoblastic leukemia, said process comprising the steps of (I) separating serum from the blood of patients of acute lymphoblastic leukemia; (ii) separation of low molecular weight fractions and galactose binding proteins from the serum on affinity matrix; (iii) passing the galactose free protein fraction obtained in step (ii) over another affinity matrix to capture O-acetyl sialic acid specific protein fraction; (iv) eluting specific protein fraction with a buffer at alkaline pH in the range of 8.0-11.Type: GrantFiled: December 3, 1999Date of Patent: February 17, 2004Inventors: Chitra Mandal, Santanu Pal, Mitali Chatterjee
-
Patent number: 6692739Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.Type: GrantFiled: August 31, 1999Date of Patent: February 17, 2004Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of The College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Patent number: 6689570Abstract: The invention relates to an antibody or antigen-binding fragment thereof which binds to the CC chemokine receptor GPR-9-6 and blocks the binding of a ligand (e.g., TECK) to the receptor. The invention also relates to a method of identifying agents (molecules, compounds) which can bind to GPR-9-6 and inhibit the binding of a ligand (e.g., TECK) and/or modulate a function of GPR-9-6. The invention further relates to a method of modulating a function of GPR-9-6, and to the use of the antibodies, antigen-binding fragments and agents identified by the method of the invention in research, therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: September 13, 2001Date of Patent: February 10, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: David P. Andrew, Brian A. Zabel, Paul D. Ponath
-
Patent number: 6686169Abstract: Reagents and methods for the detection of Staphylococcus aureus are provided. The reagents contain an antibody that binds to a capsular polysaccharide of type 5 of Staphylococcus aureus, and can be used in methods for detection of oxacillin resistant Staphylococcus aureus that escapes detection by agglutination in the presence of fibrinogen and antibodies directed against protein A of Staphylococcus.Type: GrantFiled: August 7, 2002Date of Patent: February 3, 2004Assignee: Institut PasteurInventors: Jean-Michel Fournier, Alain Boutonnier
-
Patent number: 6682736Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: December 23, 1999Date of Patent: January 27, 2004Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 6676938Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: May 17, 2001Date of Patent: January 13, 2004Assignee: Chiron S.r.L.Inventors: Giuseppe Teti, Luciano Polonelli
-
Patent number: 6667036Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells, and to treat various conditions involving leukocyte binding via P-selectin glycoprotein ligand.Type: GrantFiled: November 18, 2002Date of Patent: December 23, 2003Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
-
Patent number: RE39138Abstract: The present invention relates to monoclonal antibodies to advanced glycosylation endproducts formed in vivo and cross-reactive with advanced glycosylation endproducts formed in vitro, and to methods of diagnosis and therapy based thereon. More particularly, the invention is directed to a monoclonal antibody, or an antigen-binding fragment thereof, reactive with in vivo produced advanced glycosylation endproducts (AGEs), which monoclonal antibody or antigen binding fragment thereof demonstrates an immunological binding characteristic of monoclonal antibody 4G9 as produced by hybridoma 4G9, deposited with the American Type Culture Collection (ATCC) and assigned Accession Number CRL 11626, on Apr. 27, 1994. In a specific embodiment, the 4G9 antibody is used in a sandwich ELISA to detect ApoB-AGE, IgG-AGE, collagen-AGE, serum-AGE peptides and proteins and urinary-AGE peptides and proteins.Type: GrantFiled: December 16, 1999Date of Patent: June 20, 2006Assignee: Alteon IncorporatedInventors: Henry W. Founds, Homayoun Sadeghi
-
Patent number: RE39760Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.Type: GrantFiled: August 4, 2000Date of Patent: August 7, 2007Assignee: International Bio-Immune Systems Inc.Inventors: Kwong Y. Tsang, Myron Arlen